STUDY ON THE ACUTE AND SEMI-CHRONIC TOXICITY OF HUP A CAPSULE IN EXPERIMENTAL ANIMALS
Main Article Content
Abstract
Objectives: To evaluate the acute toxicity on Hup A soft capsules in mice and sub-chronic toxicity in rabbits. Methods: The acute toxicity was assessed in mice using the Litchfield - Wilcoxon method; the semi-chronic toxicity was assessed in rabbits according to the guidelines of the OECD and the Ministry of Health of Vietnam. The products used in this study were Hup A soft capsules, Enterprise standard. Results: After giving Hup A capsules (40.00 - 160.00 g/kg) to mice, we determined LD50 = 92.88 g/kg (79.59 - 108.39 g/kg). High dose batches of mice showed tremors, increased sweating, and then they died. With two dosage of 0.12 g/kg/24h and 0.36 g/kg/24h, rabbits were administered continuously during 42 days. The results showed that no impact was detected on some hematological parameters: Red blood cell count, white blood cell count, and hemoglobin content; indicators of liver and kidney function: AST, ALT enzyme activities, Cholesterol, Albumin, Total Bilirubin and Creatinine content, histopathology of liver and kidney cells were normal in experimental rabbits. Conclusion: Hup A capsules had LD50 = 92,88 g/kg (79,59 - 108,39 g/kg) in white mice and did not affect hematopoietic, liver, or kidney function of experimental rabbits after 42 days of study.
Article Details
Keywords
Hup A capsule, Acute toxicity, Semi-chronic toxicity, Experimental animal
References
2. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị một số rối loạn tâm thần thường gặp. Quyết định số 2058/QĐ-BYT, ngày 14/05/2020.
3. U Damar, R Gersner, J T Johnstone et al. Huperzine A as a neuroprotective and antiepileptic drug: A review of preclinical research. Expert Rep Neurother. 2016; 16(6):671-80.
4. Bộ Y tế. Hướng dẫn thử nghiệm tiền lâm sàng và lâm sàng thuốc đông y, thuốc từ dược liệu. Quyết định 141- QĐ- K2ĐT 27/10/2015.
5. Đỗ Trung Đàm. Phương pháp nghiên cứu độc tính cấp của thuốc. Nhà xuất bản Y học. Hà Nội. 2014.
6. OECD, Test No.407: Repeated Dose 28-day Oral Toxicity Study in Rodents, OECD Guidelines for the testing of Chemicals, Section 4: Health Efects. 2008.
7. Debasis Bagchi, Manashi Bagchi, Anand Swaroop et al. Huperzine A and Shankhapushpi in Brain Health. Phytopharmaceuticals for Brain Health. 2017:101-118.
8. Giang T Ha, Ryan K Wong, Yan Zhang. Huperzine aHs a potential treatment of Alzheimer’s disease: An assessment on chemistry, pharmacology, and clinical studies. Chemistry & Biodiversity. 2011; 8(7):1189-1204.
9. SS Xu, ZX Gao, Z Weng et al. Efficacy of tablet HuperzineA on memory, cognition, and behavior in Alzheimer’s disease. Zhonggou Yao Li Xue Bao. 1995; 16(5):391-395.
10. Lei Sheng, Yi Qu, Jing Yan et al. Population pharmacokinetic modeling and stimulation of huperzine A in elderly Chinese subjects. Acta Pharmacol Sin. 2016; 37(7):994-1001.